Relmada Therapeutics (RLMD) Q2 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.11

Estimate

-$0.20

Surprise

+44.4%

Score today

4.5/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Relmada Therapeutics (RLMD) reported a narrower loss than forecast — adjusted EPS of -$0.11 against the -$0.20 estimate (a 44.4% beat on a still-unprofitable quarter).

TrendMatrix currently rates RLMD Hold at 4.5/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's +44.4% surprise compares with a -199.9% four-quarter average. Next scheduled report: 2026-11-12.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$3.28

Price target

$4.56

Stop

$3.17

Upside to target

+39.0%

Model outputs from TrendMatrix’s engine as of 2026-10-07 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$371.2M

P/E (fwd)

-8.5

52-week range

$1.80–$8.00

Off 52-week high

59.0%

RSI (14)

15

Volume vs avg

1.27×

Score today

4.5/10